RET and non-small cell lung carcinoma: The RET-selective inhibitors selpercatinib (LOXO-292) and pralsetinib (BLU-667), have shown durable clinical responses in patients with NSCLC and RET fusions, including some previously treated with MKIs or chemotherapy15–17, and their efficacy can be attributed to improved selectivity for RET compared to the MKIs used previously17,18.